Hytrin Indication:

For the treatment of symptomatic benign prostatic hyperplasia (BPH) and also for hypertension.

Hytrin Mechanism Of Action:

Hytrin selectively and competitively inhibits vascular postsynaptic alpha(1)-adrenergic receptors, resulting in peripheral vasodilation and a reduction of vascular resistance and blood pressure. Unlike the nonselective alph-adrenergic blockers phenoxybenzamine and phentolamine, terazosin does not block presynaptic alpha(2)-receptors and, hence, does not cause reflex activation of norepinephrine release to produce reflex tachycardia.

Hytrin Drug Interactions:

Not Available

Hytrin Food Interactions:

Not Available

Hytrin Generic Name:

Synonyms:

  • Terazosin HCl
  • Terazosin hydrochloride
  • Terazosina [Inn-Spanish]
  • Terazosine
  • Terazosine [Inn-French]
  • Terazosinum [Inn-Latin]
  • Trazosin HCl
  • Abbott 45975

Drug Type:

Small Molecule; Approved

Absorption:

Essentially completely absorbed in man (90% bioavailability).

Toxicity (Overdose):

LD50=259.3mg/kg (i.v. in mice)

Protein Binding:

90-94%

Biotransformation:

Hepatic. One of the four metabolites identified (piperazine derivative of terazosin) has antihypertensive activity.

Half Life:

12 hours

Dosage Forms of Hytrin:

Tablet Oral

Chemical IUPAC Name:

[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone

Organisms Affected:

Humans and other mammals

Hytrin to general, pharmacology

General, pharmacology..